These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 33364967)

  • 21. Adalimumab significantly reduces inflammation and serum DKK-1 level but increases fatty deposition in lumbar spine in active ankylosing spondylitis.
    Hu Z; Xu M; Li Q; Lin Z; Liao Z; Cao S; Wei Q; Zhang YL; Li T; Jin O; Huang J; Pan Y; Wu Y; Deng X; Gu J
    Int J Rheum Dis; 2012 Aug; 15(4):358-65. PubMed ID: 22898215
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Physicochemical and Functional Characterization of HS016, a Biosimilar of Adalimumab (Humira).
    Gao D; Nie L; Yuan J; Hu F; Wu Z; Lin Q; Wang H
    J Pharm Sci; 2022 Apr; 111(4):1142-1151. PubMed ID: 34863972
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS study.
    Park W; Yoo DH; Jaworski J; Brzezicki J; Gnylorybov A; Kadinov V; Sariego IG; Abud-Mendoza C; Escalante WJ; Kang SW; Andersone D; Blanco F; Hong SS; Lee SH; Braun J
    Arthritis Res Ther; 2016 Jan; 18():25. PubMed ID: 26795209
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Maintenance of improvement in spinal mobility, physical function and quality of life in patients with ankylosing spondylitis after 5 years in a clinical trial of adalimumab.
    van der Heijde D; Breban M; Halter D; DiVittorio G; Bratt J; Cantini F; Kary S; Pangan AL; Kupper H; Rathmann SS; Sieper J; Mease PJ
    Rheumatology (Oxford); 2015 Jul; 54(7):1210-9. PubMed ID: 25541333
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical Efficacy of Modified Yanghe Decoction in Ankylosing Spondylitis: A Randomized Controlled Trial.
    Wang Y; Xiao X
    Med Sci Monit; 2018 May; 24():2912-2918. PubMed ID: 29735967
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Supervised training and home-based rehabilitation in patients with stabilized ankylosing spondylitis on TNF inhibitor treatment: a controlled clinical trial with a 12-month follow-up.
    Masiero S; Poli P; Bonaldo L; Pigatto M; Ramonda R; Lubrano E; Punzi L; Maffulli N
    Clin Rehabil; 2014 Jun; 28(6):562-72. PubMed ID: 24285801
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inflammatory back pain in psoriatic arthritis is significantly more responsive to corticosteroids compared to back pain in ankylosing spondylitis: a prospective, open-labelled, controlled pilot study.
    Haroon M; Ahmad M; Baig MN; Mason O; Rice J; FitzGerald O
    Arthritis Res Ther; 2018 Apr; 20(1):73. PubMed ID: 29665824
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Adalimumab plus methotrexate for the treatment of rheumatoid arthritis: a multi-center randomized, double-blind, placebo-controlled clinical study.].
    Huang F; Zhang FC; Bao CD; Tao Y; Gu JR; Xu JH; Zhu P; Xu HJ; Zhang ZY; Zhao DB; Wu DH
    Zhonghua Nei Ke Za Zhi; 2009 Nov; 48(11):916-21. PubMed ID: 20079321
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical similarity of the biosimilar ABP 501 compared with adalimumab after single transition: long-term results from a randomized controlled, double-blind, 52-week, phase III trial in patients with moderate-to-severe plaque psoriasis.
    Papp K; Bachelez H; Costanzo A; Foley P; Gooderham M; Kaur P; Philipp S; Spelman L; Zhang N; Strober B
    Br J Dermatol; 2017 Dec; 177(6):1562-1574. PubMed ID: 28755394
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficiency of adalimumab, etanercept and infliximab in ankylosing spondylitis in clinical practice.
    Escudero-Vilaplana V; Ramírez-Herráiz E; Alañón-Plaza E; Trovato-López N; García-Vicuña R; Carreño-Pérez L; Morell-Baladrón A; Sanjurjo-Sáez M
    Int J Clin Pharm; 2015 Oct; 37(5):808-14. PubMed ID: 25910480
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical manifestations and responsiveness to adalimumab are similar in patients with ankylosing spondylitis with and without concomitant psoriasis.
    Braun J; Rudwaleit M; Kary S; Kron M; Wong RL; Kupper H
    Rheumatology (Oxford); 2010 Aug; 49(8):1578-89. PubMed ID: 20448079
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical and MRI remission in patients with nonradiographic axial spondyloarthritis who received long-term open-label adalimumab treatment: 3-year results of the ABILITY-1 trial.
    van der Heijde D; Sieper J; Maksymowych WP; Lambert RG; Chen S; Hojnik M; Anderson JK; Pangan AL
    Arthritis Res Ther; 2018 Mar; 20(1):61. PubMed ID: 29587851
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Improved clinical, functional and work outcomes in spondyloarthritides during real-life adalimumab treatment in central-eastern Europe.
    Szántó S; Poór G; Opris D; Iaremenko O; Procházková L; Kuuse R; Nagy O; Chernyshov V; Géher P
    J Comp Eff Res; 2016 Aug; 5(5):475-85. PubMed ID: 27417564
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of a quantitative scoring of enthesitis in ankylosing spondylitis.
    Kaya A; Ozgocmen S; Kamanli A; Aydogan R; Yildirim A; Ardicoglu O
    J Clin Rheumatol; 2007 Dec; 13(6):303-6. PubMed ID: 18176136
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Colour Doppler ultrasonography can be used to detect the changes of sacroiliitis and peripheral enthesitis in patients with ankylosing spondylitis during adalimumab treatment.
    Hu Z; Xu M; Wang Q; Qi J; Lv Q; Gu J
    Clin Exp Rheumatol; 2015; 33(6):844-50. PubMed ID: 26321072
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of adalimumab among patients with moderate to severe psoriasis with co-morbidities: Subanalysis of results from a randomized, double-blind, placebo-controlled, phase III trial.
    Kimball AB; Bensimon AG; Guerin A; Yu AP; Wu EQ; Okun MM; Bao Y; Gupta SR; Mulani PM
    Am J Clin Dermatol; 2011 Feb; 12(1):51-62. PubMed ID: 21110526
    [TBL] [Abstract][Full Text] [Related]  

  • 37. FKB327, an adalimumab biosimilar, versus the reference product: results of a randomized, Phase III, double-blind study, and its open-label extension.
    Genovese MC; Glover J; Greenwald M; Porawska W; El Khouri EC; Dokoupilova E; Vargas JI; Stanislavchuk M; Kellner H; Baranova E; Matsunaga N; Alten R
    Arthritis Res Ther; 2019 Dec; 21(1):281. PubMed ID: 31831079
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of etanercept in patients with the enthesitis-related arthritis category of juvenile idiopathic arthritis: results from a phase III randomized, double-blind study.
    Horneff G; Foeldvari I; Minden K; Trauzeddel R; Kümmerle-Deschner JB; Tenbrock K; Ganser G; Huppertz HI
    Arthritis Rheumatol; 2015 May; 67(8):2240-9. PubMed ID: 25891010
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial.
    Blauvelt A; Papp KA; Griffiths CE; Randazzo B; Wasfi Y; Shen YK; Li S; Kimball AB
    J Am Acad Dermatol; 2017 Mar; 76(3):405-417. PubMed ID: 28057360
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Real-life Tolerability and Effectiveness of Adalimumab Biosimilar in Ankylosing Spondylitis: the Adalimumab Biosimilar Patient Registry Data.
    Kapoor S; Kaushik VV; Jain R; Rao VKR; Gharia M
    ACR Open Rheumatol; 2019 Oct; 1(8):480-484. PubMed ID: 31777828
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.